Warning! GuruFocus detected
1 Severe warning sign
with ZNTL.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Zentalis Pharmaceuticals Inc
NAICS : 325411
SIC : 2833
ISIN : US98943L1070
Share Class Description:
ZNTL: Ordinary SharesDescription
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.67 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.9 | |||||
| 3-Year EPS without NRI Growth Rate | 0.7 | |||||
| 3-Year FCF Growth Rate | -0.8 | |||||
| 3-Year Book Growth Rate | -6.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.47 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.84 | |||||
| 9-Day RSI | 30.88 | |||||
| 14-Day RSI | 36.08 | |||||
| 3-1 Month Momentum % | -21.36 | |||||
| 6-1 Month Momentum % | -25 | |||||
| 12-1 Month Momentum % | -84.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.29 | |||||
| Quick Ratio | 7.29 | |||||
| Cash Ratio | 7.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.9 | |||||
| Shareholder Yield % | 2.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -515.94 | |||||
| Net Margin % | -442.02 | |||||
| FCF Margin % | -424.01 | |||||
| ROE % | -42.39 | |||||
| ROA % | -33.99 | |||||
| ROIC % | -390.16 | |||||
| 3-Year ROIIC % | -399.04 | |||||
| ROC (Joel Greenblatt) % | -518.12 | |||||
| ROCE % | -44.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.01 | |||||
| PB Ratio | 0.36 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 1.01 | |||||
| EV-to-Forward-EBIT | -1.03 | |||||
| EV-to-EBITDA | 1.02 | |||||
| EV-to-Forward-EBITDA | -1.04 | |||||
| EV-to-Revenue | -5.22 | |||||
| EV-to-Forward-Revenue | 6.19 | |||||
| EV-to-FCF | 1.23 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.44 | |||||
| Earnings Yield (Greenblatt) % | 99.01 | |||||
| FCF Yield % | -133.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZNTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zentalis Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 40.56 | ||
| EPS (TTM) ($) | -2.49 | ||
| Beta | 1.31 | ||
| 3-Year Sharpe Ratio | -0.88 | ||
| 3-Year Sortino Ratio | -1.01 | ||
| Volatility % | 95.06 | ||
| 14-Day RSI | 36.08 | ||
| 14-Day ATR ($) | 0.219223 | ||
| 20-Day SMA ($) | 2.14 | ||
| 12-1 Month Momentum % | -84.17 | ||
| 52-Week Range ($) | 1.61 - 16.265 | ||
| Shares Outstanding (Mil) | 71.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zentalis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zentalis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zentalis Pharmaceuticals Inc Frequently Asked Questions
What is Zentalis Pharmaceuticals Inc(ZNTL)'s stock price today?
The current price of ZNTL is $1.81. The 52 week high of ZNTL is $16.27 and 52 week low is $1.61.
When is next earnings date of Zentalis Pharmaceuticals Inc(ZNTL)?
The next earnings date of Zentalis Pharmaceuticals Inc(ZNTL) is 2025-03-13 Est..
Does Zentalis Pharmaceuticals Inc(ZNTL) pay dividends? If so, how much?
Zentalis Pharmaceuticals Inc(ZNTL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers